BG61250B1 - Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му - Google Patents

Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му Download PDF

Info

Publication number
BG61250B1
BG61250B1 BG96686A BG9668692A BG61250B1 BG 61250 B1 BG61250 B1 BG 61250B1 BG 96686 A BG96686 A BG 96686A BG 9668692 A BG9668692 A BG 9668692A BG 61250 B1 BG61250 B1 BG 61250B1
Authority
BG
Bulgaria
Prior art keywords
compound
composition according
acid
composition
amount
Prior art date
Application number
BG96686A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG96686A (bg
Inventor
Jozsef Beres
Jun. Jozsef Beres
Original Assignee
Beres Export-Import Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beres Export-Import Rt. filed Critical Beres Export-Import Rt.
Publication of BG96686A publication Critical patent/BG96686A/bg
Publication of BG61250B1 publication Critical patent/BG61250B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
  • Circuits Of Receivers In General (AREA)
BG96686A 1991-07-24 1992-07-24 Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му BG61250B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU912492A HU207799B (en) 1991-07-24 1991-07-24 Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis

Publications (2)

Publication Number Publication Date
BG96686A BG96686A (bg) 1993-12-24
BG61250B1 true BG61250B1 (bg) 1997-04-30

Family

ID=10959658

Family Applications (1)

Application Number Title Priority Date Filing Date
BG96686A BG61250B1 (bg) 1991-07-24 1992-07-24 Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му

Country Status (18)

Country Link
US (2) US5312629A (ko)
EP (1) EP0524633B1 (ko)
JP (1) JP2673852B2 (ko)
KR (1) KR100234855B1 (ko)
AT (1) ATE178213T1 (ko)
BG (1) BG61250B1 (ko)
CA (1) CA2074639C (ko)
CZ (1) CZ281672B6 (ko)
DE (1) DE69228777T2 (ko)
FI (1) FI923364A (ko)
HR (1) HRP920192B1 (ko)
HU (1) HU207799B (ko)
PL (1) PL169684B1 (ko)
RO (1) RO109505B1 (ko)
RU (1) RU2093160C1 (ko)
SI (1) SI9200155A (ko)
SK (1) SK278944B6 (ko)
YU (1) YU48243B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US5863519A (en) * 1994-08-18 1999-01-26 Nycomed Imaging As Composition and method of MRI using both a positive and a negative contrast agent
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
GB9416768D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
RU2146146C1 (ru) * 1999-05-05 2000-03-10 Дубинина Лариса Васильевна Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
US20030170318A1 (en) * 2000-09-29 2003-09-11 Steiner Gregory Gene Fluoride compositions and uses thereof
US6638431B2 (en) * 2001-05-03 2003-10-28 Mainstream Engineering Corporation Formulation and method for treating wetted surface elements in climate control systems
KR100889994B1 (ko) * 2003-08-14 2009-03-24 한영미 녹반을 함유하는 항암활성을 갖는 조성물
KR20050018250A (ko) * 2003-08-14 2005-02-23 한영주 복합생약 조성물을 함유하는 항암활성을 갖는 조성물
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
RU2437565C2 (ru) * 2005-06-02 2011-12-27 Ю. Эс. Боракс Инк. Композиция кормового продукта для профилактики или лечения остеохондроза (варианты), способ профилактики или лечения остеохондроза
JP2010512323A (ja) * 2006-12-06 2010-04-22 ユー．エス．ボラックス インコーポレイテッド 動物飼料組成物
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (en) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Enhancement of vanadium-containing phosphatase inhibitors by polyols
US10634385B2 (en) 2009-09-03 2020-04-28 Ademco Inc. Heat balancing system
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
WO2014196841A1 (en) 2013-06-07 2014-12-11 Kael-Gemvax Co., Ltd. Biological markers useful in cancer immunotherapy
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
WO2015126265A1 (en) * 2014-02-18 2015-08-27 Santos Joyce Bedelia B Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022998B (en) * 1978-06-14 1982-09-08 Beres J Phermaceutical composition for the treatment of neoplasticand other diseases
JPS554348A (en) * 1978-06-26 1980-01-12 Peresu Yozefu Drug composition for treating variety of illness by influence to reticuloendotherial tissue and method of treating maligmant tumor with said composition in treating human

Also Published As

Publication number Publication date
HUT61475A (en) 1993-01-28
YU48243B (sh) 1997-08-22
FI923364A0 (fi) 1992-07-24
CA2074639A1 (en) 1993-01-25
HRP920192B1 (en) 2000-06-30
KR100234855B1 (ko) 1999-12-15
PL169684B1 (pl) 1996-08-30
JP2673852B2 (ja) 1997-11-05
PL295352A1 (en) 1993-02-22
RU2093160C1 (ru) 1997-10-20
US5405620A (en) 1995-04-11
YU81092A (sr) 1996-01-09
JPH06227992A (ja) 1994-08-16
SI9200155A (en) 1993-03-31
RO109505B1 (ro) 1995-03-30
SK278944B6 (sk) 1998-05-06
EP0524633B1 (en) 1999-03-31
CZ281672B6 (cs) 1996-12-11
HU207799B (en) 1993-06-28
DE69228777T2 (de) 1999-10-21
HU912492D0 (en) 1991-12-30
DE69228777D1 (de) 1999-05-06
CZ232692A3 (en) 1993-02-17
US5312629A (en) 1994-05-17
EP0524633A2 (en) 1993-01-27
ATE178213T1 (de) 1999-04-15
HRP920192A2 (hr) 1994-04-30
FI923364A (fi) 1993-01-25
KR930001915A (ko) 1993-02-22
CA2074639C (en) 1996-01-09
BG96686A (bg) 1993-12-24
EP0524633A3 (en) 1993-07-28
SK232692A3 (en) 1995-06-07

Similar Documents

Publication Publication Date Title
BG61250B1 (bg) Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му
US7375243B2 (en) Method for preparation of amino acid chelate
BAUER et al. Vitamin D intoxication with metastatic calcification
McCRORY et al. Renal excretion of inorganic phosphate in newborn infants
EP3091974B1 (en) Dosage regimen of ferric trimaltol
Lorenzo et al. Congenital dilatation of the biliary tract
HAY et al. Cation exchange resins in the treatment of congestive heart failure
Corner Hypertrophic pyloric stenosis in infancy treated with methyl scopolamine nitrate
CN105920606A (zh) 一种用于治疗小儿腹泻病的复方口服液及其制备方法
Farrell et al. Renal tubular acidosis and nephrocalcinosis: diagnosis and clinical management
THERAP section of Eberapeuticz anb Pbarmacoloop.
Youmans Mineral deficiencies
JPS63267716A (ja) 尿素サイクル代謝異常症治療剤
McChesney et al. Some applications of ion exchange resins to medical problems
CH641045A5 (en) Pharmaceutical preparation, in particular for the cure and prevention of neoplastic diseases
CN117898414A (zh) 一种富硒禁食模拟食品组合物及应用
CN101953848B (zh) 治疗癌症的药物及其用途
WO2020210608A1 (en) Liquid concentrates of calcium and magnesium
DE2827478A1 (de) Arzneimittel, insbesondere zur heilung von und vorbeugung gegen geschwulstkrankheiten
Wilcox PROGRESS OF MEDICAL SCIENCE.
Fortescue-Brickdale A practical guide to the newer remedies
JE Medical Societies.
T R U SS Libraries for Seamen’
Hydro et al. nervous strain and privation followed by the postwar
Quain RFFORTS OF CASES FROM THE OUT-PATIENT DEPARTMENT OF THE HOSPITAL FOR CONSUMPTION AND DISEASES OF THE CHEST, AT BROMPTON. WITH CLINICAL REMARKS.